Page 6 - Fernando Marques News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Reuters Staff 1 Min Read BRASILIA, Feb 2 (Reuters) - The Brazilian pharmaceutical company that will make Russia’s Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next at the latest, its Chief Executive Officer Fernando Marques said on Tuesday. Marques said the strong efficacy results from late stage trials for Sputnik V in Russia published on Tuesday by The Lancet will help speed up approval in Brazil sought by his company, Uniao Quimica. He expects production to start in April and reach 8 million doses a month by May, for sale in ...

A Brazilian pharmaceutical company met with health regulator Anvisa on Monday seeking approval to conduct Phase III clinical trials of Russia's Sputnik V COVID-19 vaccine, which it plans to make in Brazil for national immunization and for export.

[uam_ad id="317182"] RIO DE JANEIRO, BRAZIL - The Russian Sputnik V vaccine for Covid-19 is already registered in its country of origin, as well as authorized for emergency use in other countries, including Argentina, Bolivia, Venezuela and Hungary. União Química chairman Fernando Marques announced on Monday, January 25th that he plans to immediately start phase 3 trials of the Sputnik V vaccine in Brazil after ANVISA (National Health Regulatory Agency) clearance. The Subscribe to our Premium Membership Plan. Already Subscribed? Login Here